Article
Version 1
Preserved in Portico This version is not peer-reviewed
Real-World Effectiveness of Meropenem: Results of an Observational Study in 84 Colombian Patients
Version 1
: Received: 17 November 2020 / Approved: 19 November 2020 / Online: 19 November 2020 (13:34:26 CET)
A peer-reviewed article of this Preprint also exists.
Garnica-Velandia, S.; Aristizábal-Ruiz, L.A.; Alvarez-Moreno, C.A. Real-World Use of Generic Meropenem: Results of an Observational Study. Antibiotics 2021, 10, 62. Garnica-Velandia, S.; Aristizábal-Ruiz, L.A.; Alvarez-Moreno, C.A. Real-World Use of Generic Meropenem: Results of an Observational Study. Antibiotics 2021, 10, 62.
Abstract
Background. To determine the effectiveness and safety of meropenem in routine clinical practice, in terms of clinical and microbiological response. Methods. A real-world, observational, descriptive, longitudinal study with daily monitoring of clinical history records was conducted on all patients who were medically prescribed meropenem during a period between October 2015 and March 2016 at a university hospital in Bucaramanga (Colombia). Results. The study evaluated 84 patients with an average age of 63.2 years, mostly older adults with multiple comorbidities, of whom 54.8% were men. A positive clinical or microbiological response was obtained in 98.8% of the patients. At the end of the treatments, significant improvements in dysthermia (0% vs 29% at the beginning, p = 0.000), tachycardia (13% vs 47%, p = 0.049) and leukocytosis (39% vs 15% at the beginning, p = 0.008) were evidenced. The improvement in the indicator that combines all the SIRS criteria was also significant (p = 0.000). The treatment was well tolerated, although we identified some non-serious and expected adverse reactions. Conclusions. Generic meropenem proved to be effective and well tolerated for different types of infection in routine clinical practice. The results are consistent with the findings of the clinical studies with the innovator drug.
Keywords
antimicrobials; meropenem; generic drug; real-life studies; product surveillance, postmarketing; treatment outcome; pharmacovigilance
Subject
Medicine and Pharmacology, Immunology and Allergy
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment